MARKET

PDSB

PDSB

Pds Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.09
+0.11
+2.21%
After Hours: 5.00 -0.09 -1.77% 17:33 05/19 EDT
OPEN
4.980
PREV CLOSE
4.980
HIGH
5.18
LOW
4.970
VOLUME
191.71K
TURNOVER
0
52 WEEK HIGH
17.85
52 WEEK LOW
3.470
MARKET CAP
144.82M
P/E (TTM)
-6.2362
1D
5D
1M
3M
1Y
5Y
BRIEF-PDS Biotechnology Appoints Sanjay Zaveri as Senior Vice President, Business Development
reuters.com · 1d ago
PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development
Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)FLORHAM PARK, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted ...
GlobeNewswire · 1d ago
PDS Biotech to Participate at Upcoming Investor Conferences
FLORHAM PARK, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on ...
GlobeNewswire · 2d ago
Alliance Global Adjusts Price Target on PDS Biotechnology to $16 From $18, Reiterates Buy Rating
MT Newswires · 3d ago
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Recap: PDS Biotechnology Q1 Earnings
  PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/11 11:45
BRIEF-PDS Biotech Provides Business Update And Reports First Quarter 2022 Financial Results
reuters.com · 05/11 11:14
PDS Biotechnology Q1 EPS $(0.32) Misses $(0.22) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 128.57 percent decrease over losses of $(0.14) per share
Benzinga · 05/11 11:13
More
No Data
Learn about the latest financial forecast of PDSB. Analyze the recent business situations of Pds Biotechnology Corporation through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PDSB stock price target is 19.43 with a high estimate of 25.00 and a low estimate of 15.00.
High25.00
Average19.43
Low15.00
Current 5.09
EPS
Actual
Estimate
-0.26-0.19-0.13-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 79
Institutional Holdings: 11.09M
% Owned: 39.00%
Shares Outstanding: 28.45M
TypeInstitutionsShares
Increased
25
495.36K
New
20
440.42K
Decreased
11
738.79K
Sold Out
12
910.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Glover
President/Chief Executive Officer/Director
Frank Bedu-Addo
Chief Financial Officer/Chief Accounting Officer
Matthew Hill
Senior Vice President
Sanjay Zaveri
Chief Scientific Officer
Gregory Conn
Controller
Janetta Trochimiuk
Other
Lauren Wood
Director
Ilian Iliev
Independent Director
Kamil Ali-Jackson
Independent Director
Otis Brawley
Independent Director
Gregory Freitag
Independent Director
Richard Sykes
No Data
No Data
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is focused on developing a growing pipeline of cancer immunotherapy candidates and infectious disease vaccine candidates designed to overcome the limitations of immunotherapy technologies. It owns Versamune, a T-cell activating platform designed to train the immune system to destroy disease. Its lead product candidate, PDS0101, which combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products is all administered by subcutaneous injection. DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on agonist antigens from the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.